Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the nine Months Ended December 31, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017; Provides Dividend Guidance for the Year End of Fiscal Year 2017
Kawasumi Laboratories Inc. announced consolidated earnings results for the nine months ended December 31, 2016. For the period, the company reported net sales of ¥18,404 million, operating income of ¥802 million, ordinary income of ¥916 million, profit attributable to owners of the parent of ¥979 million or net income per share of ¥44.90 compared to net sales of ¥21,137 million, operating income of ¥1,594 million, ordinary income of ¥1,700 million, net income of ¥1,240 million or net income per share of ¥54.24 for the same period last year. Profit before income taxes was ¥937 million against ¥1,716 million a year ago. Net cash provided by operating activities was ¥1,805 million against ¥1,834 million a year ago. Purchase of property, plant and equipment was ¥850 million against ¥278 million a year ago. Purchase of intangible assets was ¥230 million against ¥26 million a year ago.
The company provided dividend guidance for the year end of fiscal year ending March 31, 2017. For the period, the company expects dividend of ¥7.50 per share against ¥7.50 per share a year ago.
For the full year of fiscal year ending March 31, 2017, the company expects consolidated net sales of ¥25,700 million, operating income of ¥1,150 million, ordinary income of ¥1,150 million, profit attributable to owners of the parent of ¥1,200 million or net income per share of ¥55.01.